[HTML][HTML] Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment
E Ten Hacken, JA Burger - Biochimica et Biophysica Acta (BBA)-Molecular …, 2016 - Elsevier
Abstract Chronic Lymphocytic Leukemia (CLL) is a malignancy of mature B lymphocytes
which are highly dependent on interactions with the tissue microenvironment for their …
which are highly dependent on interactions with the tissue microenvironment for their …
The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies
JA Burger, JG Gribben - Seminars in cancer biology, 2014 - Elsevier
Over the last decade, the active role of the microenvironment in the pathogenesis of B cell
lymphomas has been recognized, delivering signals that favor clonal expansion and drug …
lymphomas has been recognized, delivering signals that favor clonal expansion and drug …
CD38 and CD157: a long journey from activation markers to multifunctional molecules
V Quarona, G Zaccarello, A Chillemi… - Cytometry Part B …, 2013 - Wiley Online Library
CD38 (also known as T10) was identified in the late 1970s in the course of pioneering work
carried out at the Dana‐Farber Cancer Center (Boston, MA) that focused on the identification …
carried out at the Dana‐Farber Cancer Center (Boston, MA) that focused on the identification …
Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab
J Krejcik, KA Frerichs, IS Nijhof, B van Kessel… - Clinical cancer …, 2017 - AACR
Purpose: Daratumumab treatment results in a marked reduction of CD38 expression on
multiple myeloma cells. The aim of this study was to investigate the clinical implications and …
multiple myeloma cells. The aim of this study was to investigate the clinical implications and …
CD49d is the strongest flow cytometry–based predictor of overall survival in chronic lymphocytic leukemia
P Bulian, TD Shanafelt, C Fegan… - Journal of Clinical …, 2014 - ascopubs.org
Purpose Although CD49d is an unfavorable prognostic marker in chronic lymphocytic
leukemia (CLL), definitive validation evidence is lacking. A worldwide multicenter analysis …
leukemia (CLL), definitive validation evidence is lacking. A worldwide multicenter analysis …
Treatment with Ibrutinib Inhibits BTK- and VLA-4–Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo
SEM Herman, RZ Mustafa, J Jones, DH Wong… - Clinical Cancer …, 2015 - AACR
Purpose: Ibrutinib leads to a transient lymphocytosis in patients with chronic lymphocytic
leukemia (CLL) that develops within hours of starting drug and is due to the efflux of cells …
leukemia (CLL) that develops within hours of starting drug and is due to the efflux of cells …
Chronic lymphocytic leukemia
N Chiorazzi, SS Chen, KR Rai - Cold Spring …, 2021 - perspectivesinmedicine.cshlp.org
Patients with chronic lymphocytic leukemia can be divided into three categories: those who
are minimally affected by the problem, often never requiring therapy; those that initially …
are minimally affected by the problem, often never requiring therapy; those that initially …
Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia—focus on the B-cell receptor
E Ten Hacken, JA Burger - Clinical cancer research, 2014 - AACR
Interactions between malignant B lymphocytes and the tissue microenvironment play a
major role in the pathogenesis of chronic lymphocytic leukemia (CLL) and other B-cell …
major role in the pathogenesis of chronic lymphocytic leukemia (CLL) and other B-cell …
[HTML][HTML] Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia
E Tissino, D Benedetti, SEM Herman… - The Journal of …, 2018 - ncbi.nlm.nih.gov
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, which antagonizes B cell receptor
(BCR) signals, demonstrates remarkable clinical activity in chronic lymphocytic leukemia …
(BCR) signals, demonstrates remarkable clinical activity in chronic lymphocytic leukemia …
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation
F Pozzo, T Bittolo, F Arruga, P Bulian, P Macor… - Leukemia, 2016 - nature.com
In chronic lymphocytic leukemia (CLL), NOTCH1 mutations have been associated with
clinical resistance to the anti-CD20 rituximab, although the mechanisms behind this peculiar …
clinical resistance to the anti-CD20 rituximab, although the mechanisms behind this peculiar …